Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5175752
Max Phase: Preclinical
Molecular Formula: C23H26N2O5
Molecular Weight: 410.47
Associated Items:
ID: ALA5175752
Max Phase: Preclinical
Molecular Formula: C23H26N2O5
Molecular Weight: 410.47
Associated Items:
Canonical SMILES: CCOc1cc(O)c2c(=O)cc(-c3ccc(N4CCN(C)CC4)cc3)oc2c1OC
Standard InChI: InChI=1S/C23H26N2O5/c1-4-29-20-14-18(27)21-17(26)13-19(30-23(21)22(20)28-3)15-5-7-16(8-6-15)25-11-9-24(2)10-12-25/h5-8,13-14,27H,4,9-12H2,1-3H3
Standard InChI Key: CQKFDVDXHKLKDK-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 410.47 | Molecular Weight (Monoisotopic): 410.1842 | AlogP: 3.32 | #Rotatable Bonds: 5 |
Polar Surface Area: 75.38 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.16 | CX Basic pKa: 7.55 | CX LogP: 2.74 | CX LogD: 2.64 |
Aromatic Rings: 3 | Heavy Atoms: 30 | QED Weighted: 0.69 | Np Likeness Score: 0.18 |
1. Tian Y, Liu K, Liu R, Qiu Z, Xu Y, Wei W, Xu X, Wang J, Ding H, Li Z, Bian J.. (2022) Discovery of Potent Small-Molecule USP8 Inhibitors for the Treatment of Breast Cancer through Regulating ERα Expression., 65 (13.0): [PMID:35786929] [10.1021/acs.jmedchem.2c00013] |
Source(1):